Enhancement of Antiviral CD8(+) T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab

Background: Pembrolizumab is an immune checkpoint inhibitor against programmed cell death protein-1 (PD-1) approved for therapy in metastatic melanoma. PD-1 expression is associated with a diminished functionality in HIV-1 specific-CD8(+) T cells. It is thought that PD-1 blockade could contribute to...

Descripción completa

Detalles Bibliográficos
Autores principales: Blanch-Lombarte, Oscar, Gálvez, Cristina, Revollo, Boris, Jiménez-Moyano, Esther, Llibre, Josep M., Manzano, José Luís, Boada, Aram, Dalmau, Judith, E. Speiser, Daniel, Clotet, Bonaventura, G. Prado, Julia, Martinez-Picado, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947580/
https://www.ncbi.nlm.nih.gov/pubmed/31805700
http://dx.doi.org/10.3390/jcm8122089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947580/
https://www.ncbi.nlm.nih.gov/pubmed/31805700
http://dx.doi.org/10.3390/jcm8122089

Ejemplares similares